Investigators awarded part of $30 million in grants from Weston Brain Institute

You are here

Investigators awarded part of $30 million in grants from Weston Brain Institute

weston brain institute logo.pngWeston Brain Institute announced the allocation of more than $30 million in funding for Canadian research projects that fight brain diseases of aging.

The grants were given to incredible scientists that are focusing on projects with the potential to make the greatest impact in neurodegenerative diseases of aging, an area that is significantly underfunded in Canada.

Congratulations to the ONDRI investigators that are awardees:

  • Dr. Elizabeth Finger of Schulich School of Medicine & Dentistry: testing the safety, tolerability, and preliminary efficacy of intranasal oxytocin as a treatment for apathy, indifference, and lack of empathy in patients with frontotemporal dementia.
  • Dr. Stephen Pasternak of Schulich School of Medicine & Dentistry: investigating whether ambroxol, a cough medicine, can reduce Parkinson's disease dementia in a placebo-controlled, randomized phase IIa trial.
  • Dr. David Park of University of Ottawa: validated two proteins involved in immune system function, LRRK2-WAVE2, as a therapeutic target in Parkinson's and validated the Pink-Letm1 and the mitochondria-calcium pathway as a therapeutic target for Parkinson's disease.
  • Dr. Tarek Rajji of Centre for Addiction and Mental Health: conducting non-invasive magnetic brain stimulation in patients with mild cognitive impairment to improve memory.
  • Dr. Ekaterina Rogaeva of University of Toronto (2 grants): developed a novel method to analyze the methylation status of C9orf72 repeat expansions with the goal of developing biomarkers for ALS and FTD.
  • Dr. Carmela Tartaglia of University Health Network: testing a novel tau-binding PET imaging tracer to diagnose chronic traumatic encephalopathy in retired CFL athletes and to differentiate them from Alzheimer's disease patients.
  • Dr. Mario Masellis of Sunnybrook Health Sciences Centre: identifying genomic and neuro imaging biomarkers using patient data from the GENetic Frontotemporal dementia initiative (GENFI) program.
  • Dr. Donald Weaver of University Health Network: synthesizing small molecules that can prevent the misfolding of tau protein to treat PSP and FTD.

Read more.